Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of G1T28-1 in healthy volunteers
NL-OMON42109Phase 1Active, not recruiting
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of trilaciclib in myelosuppression (3 arms), sponsored by G1 Therapeutics, Inc. Primary endpoint: Safety and tolerability of intravenous G1T28-1. Started Aug 2014; status: active, not recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NL-OMON42109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42109.